Page last updated: 2024-09-02

fingolimod hydrochloride and Amyotrophic Lateral Sclerosis

fingolimod hydrochloride has been researched along with Amyotrophic Lateral Sclerosis in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Gotoh, Y; Jantrapirom, S; Lo Piccolo, L; Nimlamool, W; Potikanond, S; Prachayasittikul, V; Umegawachi, T; Yamaguchi, M; Yeewa, R; Yoshida, H	1
Appel, S; Atassi, N; Berry, JD; Gill, A; Goyal, N; Grasso, DL; Macklin, EA; Mateen, F; Mejia, NI; Paganoni, S; Perrin, S; Rivner, M; Simpson, E; Tassinari, V; Vieira, F	1
Armida, M; De Simone, R; Mazziotti, V; Minghetti, L; Pèzzola, A; Popoli, P; Potenza, RL	1

Trials

1 trial(s) available for fingolimod hydrochloride and Amyotrophic Lateral Sclerosis

Article	Year
Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. Muscle & nerve, 2017, Volume: 56, Issue:6 Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Bradycardia; Fatigue; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Single-Blind Method	2017

Other Studies

2 other study(ies) available for fingolimod hydrochloride and Amyotrophic Lateral Sclerosis

Article	Year
A Novel Drosophila-based Drug Repurposing Platform Identified Fingolimod As a Potential Therapeutic for TDP-43 Proteinopathy. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2023, Volume: 20, Issue:5 Topics: Amyotrophic Lateral Sclerosis; Animals; DNA-Binding Proteins; Drosophila; Drug Repositioning; Fingolimod Hydrochloride; TDP-43 Proteinopathies	2023
Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2016, Volume: 13, Issue:4 Topics: Amyotrophic Lateral Sclerosis; Animals; Body Weight; Brain; Cytokines; Disease Models, Animal; Fingolimod Hydrochloride; Forkhead Transcription Factors; Gene Expression Regulation; Humans; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Mice, Transgenic; Movement Disorders; Mutation; Nitric Oxide Synthase Type II; Spinal Cord; Superoxide Dismutase	2016

Article

Year

A Novel Drosophila-based Drug Repurposing Platform Identified Fingolimod As a Potential Therapeutic for TDP-43 Proteinopathy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2023, Volume: 20, Issue:5

Topics: Amyotrophic Lateral Sclerosis; Animals; DNA-Binding Proteins; Drosophila; Drug Repositioning; Fingolimod Hydrochloride; TDP-43 Proteinopathies

2023

Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2016, Volume: 13, Issue:4

Topics: Amyotrophic Lateral Sclerosis; Animals; Body Weight; Brain; Cytokines; Disease Models, Animal; Fingolimod Hydrochloride; Forkhead Transcription Factors; Gene Expression Regulation; Humans; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Mice, Transgenic; Movement Disorders; Mutation; Nitric Oxide Synthase Type II; Spinal Cord; Superoxide Dismutase

2016